谷歌浏览器插件
订阅小程序
在清言上使用
VIPCreated with Sketch.

Two-year Follow-Up Data on the Efficacy and Safety of KN026, a HER2-targeted Bispecific Antibody Combined with Docetaxel As First-Line Treatment for HER2-positive Recurrent/metastatic Breast Cancer

Q. Zhang,J. Wang,Q. Ouyang,X. Wang,D. Lin,L. Gan,Z. Ouyang,T. Xu, Y. Liu, Y. Lv

ANNALS OF ONCOLOGY（2023）

引用 0|浏览25
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要